Latest News and Press Releases

PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) is a devastating genetic cardiac disease affecting approximately 60,000 individuals in the United States LX2020 preclinical studies demonstrated...

LX2006 is the first investigational gene therapy for the treatment of Friedreich’s ataxia cardiomyopathy Initial data from the first two cohorts, including myocardial protein expression and...

NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) --  LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing adeno-associated virus (AAV)-based gene therapy candidates for genetically...

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, Inc. (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates for...

NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, Inc. (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates for...

Eric Adler, M.D., joins LEXEO as Chief Scientific Officer New Scientific Advisory Board comprised of molecular cardiology, cardiovascular imaging, cardiac gene-editing, and RNA biology experts NEW...

- Presentations at the International Congress for Ataxia Research (ICAR) will feature LEXEO’s LX2006 gene therapy program for Friedreich’s ataxia (FA) cardiomyopathy - - A presentation at American...

– LX1004 is an adeno-associated virus (AAV) based gene therapy for the treatment of CLN2 Batten disease – – In a completed Phase 1/2 clinical trial, LX1004 demonstrated a favorable safety profile and...

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, Inc. (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates for...

Preclinical studies support clinical development of pipeline programs, including novel gene therapies for the treatment of genetically defined cardiovascular and central nervous system diseases NEW...